Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2025; 16(12): 114275
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.114275
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.114275
Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade
Gizem Calibasi-Kocal, Department of Translational Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35330, Türkiye
Author contributions: Calibasi-Kocal G conceived the overall concept, developed the manuscript outline, contributed to the discussion and design, conducted the literature review, and drafted, revised, and edited the manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gizem Calibasi-Kocal, PhD, Department of Translational Oncology, Institute of Oncology, Dokuz Eylul University, Cumhuriyet Bulvarı 144, Alsancak, Izmir 35330, Türkiye. gizem.calibasi@deu.edu.tr
Received: September 15, 2025
Revised: October 6, 2025
Accepted: December 19, 2025
Published online: December 24, 2025
Processing time: 99 Days and 6.9 Hours
Revised: October 6, 2025
Accepted: December 19, 2025
Published online: December 24, 2025
Processing time: 99 Days and 6.9 Hours
Core Tip
Core Tip: Dai et al’s research study explores the association between inflammatory cytokines and cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). Elevated levels of interleukin (IL)-6 and IL-8 were identified as key risk factors contributing to cisplatin resistance in NSCLC. Notably, IL-6 inhibition via the receptor antagonist tocilizumab restored DDP sensitivity and attenuated malignant phenotypes in resistant cell lines, by reducing cell viability, migration, and invasion, while enhancing apoptosis. These findings highlight the tumor microenvironment-cytokine interplay, particularly IL-6 signaling, as a critical determinant and potential therapeutic avenue in overcoming DDP resistance in NSCLC.